VERSARTIS Sample Clauses

VERSARTIS. VERSARTIS shall have the exclusive ownership of any Improvements that (i) relate directly to the physical or chemical structure or composition and/or amino acid or DNA sequence of the Product, the biological, chemical and/or pharmaceutical properties of the Product, or the use of the Product, and (ii) do not cover or claim BI Background IP or BI Improvements (collectively, “VERSARTIS Improvements”). VERSARTIS shall control patent prosecution and maintenance thereof. BI agrees to assign and hereby assigns, and hereby covenants that it shall cause its Affiliated Companies to assign, to VERSARTIS all right title and interest it or its Affiliated Company have or may have in any VERSARTIS Improvements. BI shall provide reasonable assistance to VERSARTIS for any action that may be necessary to assign or otherwise transfer any rights to VERSARTIS Improvements contemplated by this Section 9.2.1, including by signing any documents or other instruments to effect or perfect or record such assignments. BI shall notify VERSARTIS within [*] days of becoming aware of such VERSARTIS Improvements. Additionally, VERSARTIS shall have the exclusive ownership of any Improvements to the Manufacturing Process that result from agreed upon development and/or optimization 41 / 70 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Commercial Supply Agreement, BI/ VERSARTIS Execution Version services provided to VERSARTIS either by BI (and/or by its Affiliated Companies) alone or in collaboration with VERSARTIS and/or a third party (“VERSARTIS Manufacturing Process Improvements”). All such VERSARTIS Manufacturing Process Improvements shall be deemed to be included in the ”VERSARTIS Improvements” for all purposes of ownership and assignment obligations under this Section 9.2.1.
Sample 1
AutoNDA by SimpleDocs

Related to VERSARTIS

  • Baxter and Nexell shall cooperate in any action taken by a third party solely involving a nullity action, opposition, reexamination or any other action taken by such third party alleging the invalidity or unenforceability of any Licensed Intellectual Property. Both parties agree to share equally in the cost of the defense of such Licensed Intellectual Property.

  • Motorola retains the right to subcontract, in whole or in part, any effort required to fulfill its obligations under this Agreement, provided Motorola shall remain liable for performance hereunder.

  • Cornerstone shall notify the LLC and confirm such advice in writing (i) when the filing of any post-effective amendment to the Registration Statement or supplement to the Prospectus is required, when the same is filed and, in the case of the Registration Statement and any post-effective amendment, when the same becomes effective, (ii) of any request by the Securities and Exchange Commission for any amendment of or supplement to the Registration Statement or the Prospectus or for additional information and (iii) of the entry of any stop order suspending the effectiveness of the Registration Statement or the initiation or threatening of any proceedings for that purpose, and, if such stop order shall be entered, Cornerstone shall use its best efforts promptly to obtain the lifting thereof.

  • Principal Investigator The term “Principal Investigator” shall mean Xx. Xxxxxxx, together with such replacement persons selected in accordance with the provisions of Section 2.2 hereof.

  • Joint Manufacturing Committee A joint manufacturing committee (the “Joint Manufacturing Committee” or “JMC”) will be established pursuant to the Supply Agreement. The roles and responsibilities of the JMC shall be as specified in the Supply Agreement.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • AMD to the Fixed Interest Account, beginning with the date of such transfer, shall be credited with the Current Rate of Interest under this contract which was in effect on the date the transferred contribution was originally deposited into the Fixed Interest Account under the previous AUL contract.

  • Newco Prior to the Effective Time, Newco shall not conduct any business or make any investments other than as specifically contemplated by this Agreement and will not have any assets (other than the minimum amount of cash required to be paid to Newco for the valid issuance of its stock to the Parent).

  • WHERXXX xx xxx xxxxxxx xxxxxx xx xxx xxxxxxxx, the Seller purchases certain retail installment sale contracts secured by new and used automobiles and light duty trucks from motor vehicle dealers.

Time is Money Join Law Insider Premium to draft better contracts faster.